Similar articles

• Immunogenicity of biopharmaceuticals in laboratory animals.

  Wierda D, Smith HW, Zwickl CM. Wierda D, et al. Toxicology. 2001 Feb 2;158(1-2):71-4. doi: 10.1016/s0300-483x(00)00410-8. Toxicology. 2001. PMID: 11164995 Review.
• Safety immunopharmacology: evaluation of the adverse potential of pharmaceuticals on the immune system.

  Descotes J. Descotes J. J Pharmacol Toxicol Methods. 2012 Sep;66(2):79-83. doi: 10.1016/j.vascn.2012.05.001. Epub 2012 May 14. J Pharmacol Toxicol Methods. 2012. PMID: 22587937 Free PMC article.
• Adverse drug reactions.

  Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Pirmohamed M, et al. BMJ. 1998 Apr 25;316(7140):1295-8. doi: 10.1136/bmj.316.7140.1295. BMJ. 1998. PMID: 9554902 Free PMC article. Review. No abstract available.
• Assessing immunotoxicity: guidelines.

  Putman E, van der Laan JW, van Loveren H. Putman E, et al. Fundam Clin Pharmacol. 2003 Oct;17(5):615-26. doi: 10.1046/j.1472-8206.2003.00181.x. Fundam Clin Pharmacol. 2003. PMID: 14703723 Review.
• Immunotoxicology: clinical consequences.

  Luster MI. Luster MI. Toxicol Ind Health. 1996 May-Aug;12(3-4):533-5. doi: 10.1177/074823379601200324. Toxicol Ind Health. 1996. PMID: 8843569 Review. No abstract available.